{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:42:42Z","timestamp":1771461762891,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1007\/s11886-004-0041-8","type":"journal-article","created":{"date-parts":[[2007,5,26]],"date-time":"2007-05-26T08:19:24Z","timestamp":1180167564000},"page":"379-384","source":"Crossref","is-referenced-by-count":32,"title":["Drugs that cause torsades de pointes and increase the risk of sudden cardiac death"],"prefix":"10.1007","volume":"6","author":[{"given":"Deborah L.","family":"Wolbrette","sequence":"first","affiliation":[]}],"member":"297","reference":[{"key":"41_CR1","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/0002-8703(86)90010-4","volume":"111","author":"DM Roden","year":"1986","unstructured":"Roden DM, Woosley RL, Primm RK: Incidence and clinical features of the quinidine-associated long QT syndrome: Implications for patient care. Am Heart J 1986, 111:1088\u20131093. This early article identified risk factors for development of TdP, and estimated risks with quinidine, leading to change in clinical management of patients on the drug.","journal-title":"Am Heart J"},{"key":"41_CR2","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/00005344-200111000-00010","volume":"38","author":"T Yang","year":"2001","unstructured":"Yang T, Snyders D, Roden DM: Drug block of IKr: Model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol 2001, 38:737\u2013744.","journal-title":"J Cardiovasc Pharmacol"},{"key":"41_CR3","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1161\/01.CIR.94.10.2535","volume":"94","author":"MH Lehmann","year":"1996","unstructured":"Lehmann MH, Hardy S, Archibald D, et al.: Sex differences in risks of torsade de pointes with d, l-sotalol. Circulation 1996, 94:2534\u20132541. Data presented in this article showed women to be at increased risk of developing TdP while taking sotalol.","journal-title":"Circulation"},{"key":"41_CR4","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0002-9149(98)00006-X","volume":"81","author":"CM Pratt","year":"1998","unstructured":"Pratt CM, Camm AJ, Cooper W, et al.: Mortality in the survival with oral D-sotalol (SWORD) trial: why did patients die? Am J Cardiol 1998, 81:869\u2013876.","journal-title":"Am J Cardiol"},{"key":"41_CR5","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1056\/NEJM199909163411201","volume":"341","author":"C Torp-Pedersen","year":"1999","unstructured":"Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al., for the Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group: Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 1999, 341: 857\u2013865.","journal-title":"N Engl J Med"},{"key":"41_CR6","doi-asserted-by":"crossref","first-page":"40D","DOI":"10.1016\/S0002-9149(98)00152-0","volume":"81","author":"R Karam","year":"1998","unstructured":"Karam R, Marcello S, Brooks RR, et al.: Azimilide Dihydrochloride, a novel antiarrhythmic agent. Am J Cardiol 1998, 81:40D-46D.","journal-title":"Am J Cardiol"},{"key":"41_CR7","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1067\/mhj.2002.120969","volume":"143","author":"RL Page","year":"2002","unstructured":"Page RL, Connolly SJ, Wilkinson WE, et al., and the Azimilide Supraventricular Arrhythmia Program (ASAP) Investigators: Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: efficacy and dose-response. Am Heart J 2002, 143:643\u2013649.","journal-title":"Am Heart J"},{"key":"41_CR8","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/j.1540-8167.1995.tb00368.x","volume":"6","author":"SH Hohnloser","year":"1995","unstructured":"Hohnloser SH, Singh BN: Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. J Cardiovasc Electrophysiol 1995, 6:920\u2013936. Excellent reference regarding TdP with antiarrhythmic drugs.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"41_CR9","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1046\/j.1540-8167.2003.03441.x","volume":"14","author":"DM Roden","year":"2003","unstructured":"Roden DM: Antiarrhythmic drugs: past, present, and future. J Cardiovasc Electrophysiol 2003, 14:1389\u20131396.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"41_CR10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003088-200038010-00003","volume":"38","author":"GK Dresser","year":"2000","unstructured":"Dresser GK, Spence JD, Bailey DG: Pharmacokinetic-Pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000, 38:41\u201357. Provides clear explanation of the complicated role of cytochrome P450 3A4 inhibition in the development of TdP.","journal-title":"Clin Pharmacokinet"},{"key":"41_CR11","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1001\/jama.1993.03500120070028","volume":"269","author":"RL Woosley","year":"1993","unstructured":"Woosley RL, Chen Y, Freiman JP, et al.: Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993, 269:1532\u20131536. This early article helps provide insight into the mechanism of terfenadine-related TdP. The authors increased awareness of CYP3A4 drug interactions.","journal-title":"JAMA"},{"key":"41_CR12","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/S0735-1097(96)00352-X","volume":"28","author":"VR Vorperian","year":"1996","unstructured":"Vorperian VR, Zhou Z, Mohammad S, et al.: Torsade de pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole. J Am Coll Cardiol 1996, 28:1556\u20131561.","journal-title":"J Am Coll Cardiol"},{"key":"41_CR13","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1540-8159.1999.tb00512.x","volume":"22","author":"Y Hayashi","year":"1999","unstructured":"Hayashi Y, Ibeda U, Hashimoto T, et al.: Torsade de pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia. PACE 1999, 22(Part 1): 672\u2013674.","journal-title":"PACE"},{"key":"41_CR14","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1046\/j.1460-9592.2001.01575.x","volume":"24","author":"TW Koh","year":"2001","unstructured":"Koh TW: Risks of torsade de pointes from oral erythromycin with concomitant carbimazole (methimazole) administration. PACE 2001, 24:1575\u20131576.","journal-title":"PACE"},{"key":"41_CR15","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1016\/S0735-1097(96)00377-4","volume":"28","author":"C Antzelevitch","year":"1996","unstructured":"Antzelevitch C, Sun ZQ, Zhang ZQ, et al.: Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. J Am Coll Cardiol 1996, 28:1836\u20131848.","journal-title":"J Am Coll Cardiol"},{"key":"41_CR16","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/j.1540-8167.1998.tb00888.x","volume":"9","author":"J Vitola","year":"1998","unstructured":"Vitola J, Vukanovic J, Roden DM: Cisapride-induced torsade de pointes. J Cardiovasc Electrophysiol 1998, 9:1109\u20131113.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"41_CR17","first-page":"22","volume":"33","author":"RK Piquette","year":"1999","unstructured":"Piquette RK: Torsade de pointes induced by cisapride\/clarithromycin interactions. Am Phamacother 1999, 33:22\u201326.","journal-title":"Am Phamacother"},{"key":"41_CR18","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S0009-9236(98)90137-0","volume":"64","author":"AD Haarst van","year":"1998","unstructured":"van Haarst AD, van't Klooster GAE, van Gerven JMA, et al.: The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. Clin Pharmacol Ther 1998, 64:542\u2013546.","journal-title":"Clin Pharmacol Ther"},{"key":"41_CR19","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1176\/appi.ajp.158.11.1774","volume":"158","author":"AH Glassman","year":"2001","unstructured":"Glassman AH, Bigger JT Jr: Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001, 158:1774\u20131782.","journal-title":"Am J Psychiatry"},{"key":"41_CR20","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.2165\/00003495-200262110-00006","volume":"62","author":"PM Haddad","year":"2002","unstructured":"Haddad PM, Anderson IM: Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002, 62:1649\u20131671.","journal-title":"Drugs"},{"key":"41_CR21","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/00004714-200006000-00005","volume":"20","author":"DA Flockhart","year":"2000","unstructured":"Flockhart DA, Drici MD, Kerbusch T, et al.: Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with tourette syndrome. J Clin Psychopharmacol 2000, 20:317\u2013324.","journal-title":"J Clin Psychopharmacol"},{"key":"41_CR22","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/sj.bjp.0705283","volume":"139","author":"D Thomas","year":"2003","unstructured":"Thomas D, Wu K, Kath\u00f6fer S, et al.: The antipsychotic drug chlorpromazine inhibits HERG potassium channels. Br J Pharmacol 2003, 139:567\u2013574.","journal-title":"Br J Pharmacol"},{"key":"41_CR23","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/0002-8703(86)90660-5","volume":"111","author":"J Manouvrier","year":"1986","unstructured":"Manouvrier J, Sagot M, Caron C, et al.: Nine case of torsade de pointes with bepridil administration. Am Heart J 1986, 111:1005\u20131007.","journal-title":"Am Heart J"},{"key":"41_CR24","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/0002-9149(90)90494-L","volume":"66","author":"B Lecocq","year":"1990","unstructured":"Lecocq B, Lecocq V, Prost PL, et al.: Effects of bepridil and CERM 4205 (ORG 30701) on the relation between cardiac cycle length and QT duration in healthy volunteers. Am J Cardiol 1990, 66:636\u2013641.","journal-title":"Am J Cardiol"},{"key":"41_CR25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1161\/01.CIR.0000109484.00668.CE","volume":"109","author":"B Drolet","year":"2004","unstructured":"Drolet B, Simard C, Roden DM: Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents. Circulation 2004, 109:26\u201329.","journal-title":"Circulation"},{"key":"41_CR26","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/0002-9149(91)90502-C","volume":"68","author":"KM Stein","year":"1991","unstructured":"Stein KM, Fenton C: Incidence of QT interval prolongation during pentamidine therapy of pneumocystis carinii pneumonia. Am J Cardiol 1991, 68:1091\u20131094.","journal-title":"Am J Cardiol"},{"key":"41_CR27","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1046\/j.1540-8167.2002.00936.x","volume":"13","author":"CR Kroll","year":"2002","unstructured":"Kroll CR, Gettes LS: T wave alternans and torsades de pointes after the use of intravenous pentamidine. J Cardiovasc Electrophysiol 2002, 13:936\u2013938.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"41_CR28","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1046\/j.1365-2125.1998.00671.x","volume":"45","author":"OO Simooya","year":"1998","unstructured":"Simooya OO, Sijumbil G, Lennard MS, et al.: Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians. Br J Clin Pharmacol 1998, 45:315\u2013317.","journal-title":"Br J Clin Pharmacol"},{"key":"41_CR29","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/pmj.77.907.344","volume":"77","author":"RJR Mansfield","year":"2001","unstructured":"Mansfield RJR, Thomas RD: Drug induced long QT syndrome. Postgrad Med J 2001, 77:344, 352-353.","journal-title":"Postgrad Med J"},{"key":"41_CR30","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S0140-6736(95)92711-5","volume":"346","author":"JL Clemessy","year":"1995","unstructured":"Clemessy JL, Favier C, Borron SW, et al.: Hypokalaemia related to acute chloroquine ingestion. Lancet 1995, 346:877\u2013880.","journal-title":"Lancet"},{"key":"41_CR31","doi-asserted-by":"crossref","first-page":"501","DOI":"10.7326\/0003-4819-137-6-200209170-00010","volume":"137","author":"MJ Krantz","year":"2002","unstructured":"Krantz MJ, Lewkowiez L, Hays H, et al.: Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 2002, 137:501\u2013504.","journal-title":"Ann Intern Med"},{"key":"41_CR32","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1001\/jama.1993.03510210076031","volume":"270","author":"RR Makkar","year":"1993","unstructured":"Makkar RR, Framm BS, Steinman RT, et al.: Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993, 270:2590\u20132597. This important review showed women to be at increased risk of developing TdP with all cardiovascular drugs that prolong the QT interval.","journal-title":"JAMA"},{"key":"41_CR33","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1001\/jama.280.20.1774","volume":"280","author":"MD Drici","year":"1998","unstructured":"Drici MD, Knollman BC, Wang WX, et al.: Cardiac actions of erythromycin: Influence of female sex. JAMA 1998, 280:1774\u20131776.","journal-title":"JAMA"},{"key":"41_CR34","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0002-8703(96)90095-2","volume":"131","author":"J Reinoehl","year":"1996","unstructured":"Reinoehl J, Frankovich D, Machado C, et al.: Probucolassociated tachyarrhythmic events and QT prolongation: importance of gender. Am Heart J 1996, 131:1184\u20131191.","journal-title":"Am Heart J"},{"key":"41_CR35","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0735-1097(96)00454-8","volume":"29","author":"MH Lehmann","year":"1997","unstructured":"Lehmann MH, Timothy KW, Frankovich D, et al.: Age-gender influence on the rate-corrected QT interval and the QT heart rate relation in families with genotypically characterized long QT syndrome. J Am Coll Cardiol 1997, 29:93\u201399.","journal-title":"J Am Coll Cardiol"},{"key":"41_CR36","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1046\/j.1460-9592.2003.00137.x","volume":"26","author":"S Atar","year":"2003","unstructured":"Atar S, Freedberg NA, Antonelli D, et al.: Torsades de pointes and QT prolongation due to a combination of loratadine and amiodarone. PACE 2003, 26:785\u2013786.","journal-title":"PACE"},{"key":"41_CR37","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1540-8159.1998.tb00148.x","volume":"21","author":"DM Roden","year":"1998","unstructured":"Roden DM: Taking the \u201cidio\u201d out of \u201cidiosyncratic\u201d: predicting torsades de pointes. Pacing Clin Electrophysiol 1998, 21:1029\u20131034. This editorial proposes the concept of \u201crepolarization reserve\u201d to predict the risk of TdP in a given individual.","journal-title":"Pacing Clin Electrophysiol"},{"key":"41_CR38","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1161\/01.CIR.99.4.529","volume":"99","author":"SG Priori","year":"1999","unstructured":"Priori SG, Napolitano C, Schwartz PJ: Low penetrance in the long-QT syndrome. Circulation 1999, 99:529\u2013533. This report points out the low penetrance of long QT syndrome in some families and underscores the importance of molecular screening to look for carriers of gene mutations.","journal-title":"Circulation"},{"key":"41_CR39","doi-asserted-by":"crossref","first-page":"S291","DOI":"10.1046\/j.1540-8167.2003.90406.x","volume":"14","author":"S Freeland","year":"2003","unstructured":"Freeland S, Worthy C, Zolnierz M: Initiation and monitoring of class III antiarrhythmic agents. J Cardiovasc Electrophysiol 2003, 14:S291-S295.","journal-title":"J Cardiovasc Electrophysiol"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-004-0041-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-004-0041-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-004-0041-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T23:55:59Z","timestamp":1559433359000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-004-0041-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["41"],"URL":"https:\/\/doi.org\/10.1007\/s11886-004-0041-8","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}